PE20080607A1 - Formulacion en aerosol para la inhalacion de beta-agonistas - Google Patents
Formulacion en aerosol para la inhalacion de beta-agonistasInfo
- Publication number
- PE20080607A1 PE20080607A1 PE2007001103A PE2007001103A PE20080607A1 PE 20080607 A1 PE20080607 A1 PE 20080607A1 PE 2007001103 A PE2007001103 A PE 2007001103A PE 2007001103 A PE2007001103 A PE 2007001103A PE 20080607 A1 PE20080607 A1 PE 20080607A1
- Authority
- PE
- Peru
- Prior art keywords
- hydroxy
- dimethyl
- oxazin
- ona
- ethylamine
- Prior art date
Links
- 239000000443 aerosol Substances 0.000 title 1
- 229940125388 beta agonist Drugs 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- DUMKDWRRTLFHTA-UHFFFAOYSA-N 1-(4-methoxyphenyl)-2-methylpropan-2-amine Chemical compound COC1=CC=C(CC(C)(C)N)C=C1 DUMKDWRRTLFHTA-UHFFFAOYSA-N 0.000 abstract 1
- -1 4-HYDROXY-2,6-DIMETHYL-PHENYL Chemical class 0.000 abstract 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 abstract 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 abstract 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 abstract 1
- 206010011732 Cyst Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 208000011623 Obstructive Lung disease Diseases 0.000 abstract 1
- 206010037423 Pulmonary oedema Diseases 0.000 abstract 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 150000001450 anions Chemical class 0.000 abstract 1
- 229960005070 ascorbic acid Drugs 0.000 abstract 1
- 235000010323 ascorbic acid Nutrition 0.000 abstract 1
- 239000011668 ascorbic acid Substances 0.000 abstract 1
- 229960004495 beclometasone Drugs 0.000 abstract 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 abstract 1
- 229960004436 budesonide Drugs 0.000 abstract 1
- 208000031513 cyst Diseases 0.000 abstract 1
- 239000013583 drug formulation Substances 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 229960002714 fluticasone Drugs 0.000 abstract 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 abstract 1
- 239000008263 liquid aerosol Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000005333 pulmonary edema Diseases 0.000 abstract 1
- 229910021653 sulphate ion Inorganic materials 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Otolaryngology (AREA)
- Dispersion Chemistry (AREA)
- Virology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
SE REFIERE A UNA FORMULACION MEDICAMENTOSA LIQUIDA EN AEROSOL, CUYOS COMPONENTES SON, UN PRINCIPIO ACTIVO I; DONDE R1 Y R2 SON CADA UNO H, ALQUILO C1-C4, O ALQUILO C1-C4, O HALOGENO; R3 ES H, OH, -O-ALQUILEN C1-C4, ENTRE OTROS; X- ES UN ANION DE CARGA NEGATIVA SIMPLE O MULTIPLE, COMO CLORURO, BROMURO, YODURO, SULFATO, ENTRE OTROS; OPCIONAMENTE, PUEDE CONTENER BUDESONIDA, BECLOMETASONA, FLUTICASONA, ENTRE OTROS, Y UN COADYUVANTE, COMO ACIDO ASCORBICO, BHA, BENZOATOS, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: NETANOSULFONATO DE 6-HIDROXI-8-{1-HIDROXI-2-[2-(4-HIDROXI-2,6-DIMETIL-FENIL)-1,1-DIMETIL-ETILAMINO]-ETIL}-4H-BENZO[1,4]OXAZIN-3-ONA, HIDROCLORURO DE 6-HIDROXI-8-{1-HIDROXI-2-[2-(4-METOXI-FENIL)-1,1-DIMETIL-ETILAMINO]-ETIL}-4H-BENZO[1,4]OXAZIN-3-ONA, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION Y UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES PULMONARES OBSTRUCTIVAS, FIBROSIS CISTICA, EDEMA PULMONAR
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06119129 | 2006-08-18 | ||
| EP07101128 | 2007-01-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20080607A1 true PE20080607A1 (es) | 2008-07-17 |
Family
ID=39082381
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2007001103A PE20080607A1 (es) | 2006-08-18 | 2007-08-16 | Formulacion en aerosol para la inhalacion de beta-agonistas |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20080041370A1 (es) |
| EP (1) | EP2054034A2 (es) |
| JP (1) | JP2010501021A (es) |
| KR (1) | KR20090040922A (es) |
| AR (1) | AR062424A1 (es) |
| AU (1) | AU2007285746A1 (es) |
| BR (1) | BRPI0715692A2 (es) |
| CA (1) | CA2660480A1 (es) |
| CO (1) | CO6150123A2 (es) |
| EA (1) | EA200900267A1 (es) |
| IL (1) | IL197024A0 (es) |
| MX (1) | MX2009001553A (es) |
| NO (1) | NO20090410L (es) |
| PE (1) | PE20080607A1 (es) |
| TW (1) | TW200817010A (es) |
| UY (1) | UY30543A1 (es) |
| WO (1) | WO2008020056A2 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7056916B2 (en) * | 2002-11-15 | 2006-06-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Medicaments for the treatment of chronic obstructive pulmonary disease |
| US20050255050A1 (en) * | 2004-05-14 | 2005-11-17 | Boehringer Ingelheim International Gmbh | Powder formulations for inhalation, comprising enantiomerically pure beta agonists |
| US7220742B2 (en) | 2004-05-14 | 2007-05-22 | Boehringer Ingelheim International Gmbh | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments |
| JP5270343B2 (ja) * | 2005-08-15 | 2013-08-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ベータミメティックスの製造方法 |
| MX2014001556A (es) | 2011-08-12 | 2014-03-31 | Boehringer Ingelheim Vetmed | Composicion farmaceutica de sabor enmascarado. |
| WO2014016548A2 (en) | 2012-07-27 | 2014-01-30 | Cipla Limited | Pharmaceutical composition |
| LT3473255T (lt) | 2012-12-21 | 2022-03-10 | Boehringer Ingelheim Vetmedica Gmbh | Farmacinė vaisto forma, apimanti ciklezonidą |
| MX368306B (es) * | 2012-12-21 | 2019-09-27 | Boehringer Ingelheim Vetmedica Gmbh | Ciclesonida para el tratamiento de la enfermedad de las vias respiratorias en caballos. |
| US9944618B2 (en) | 2013-03-14 | 2018-04-17 | Mayo Foundation For Medical Education And Research | Inhibiting neurotransmitter reuptake |
| PT3157522T (pt) | 2014-06-18 | 2019-12-13 | Boehringer Ingelheim Vetmedica Gmbh | Antagonistas muscarínicos e suas combinações para os tratamentos de doenças das vias respiratórias em cavalos |
| WO2017060386A1 (de) | 2015-10-09 | 2017-04-13 | Boehringer Ingelheim International Gmbh | Verfahren zur beschichtung mikrostrukturierter bauteile |
| US20210322309A1 (en) * | 2020-04-16 | 2021-10-21 | Cai Gu Huang | Inhalable Formulation of a Solution Containing Olodaterol |
| CN115397417A (zh) * | 2020-04-16 | 2022-11-25 | 广州谷森制药有限公司 | 含有噻托溴铵和奥达特罗的可吸入溶液制剂 |
| US20220031712A1 (en) * | 2020-06-23 | 2022-02-03 | Cai Gu Huang | Preparation of a pharmaceutical composition of olodaterol and budesonide |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3134590A1 (de) * | 1981-09-01 | 1983-03-10 | Boehringer Ingelheim KG, 6507 Ingelheim | Neue benzo-heterocyclen |
| KR890000664B1 (ko) * | 1981-10-19 | 1989-03-22 | 바리 안소니 뉴우샘 | 미분된 베클로메타손 디프로피오네이트 일수화물의 제조방법 |
| DE19653969A1 (de) * | 1996-12-20 | 1998-06-25 | Boehringer Ingelheim Kg | Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole |
| US6960597B2 (en) * | 2000-06-30 | 2005-11-01 | Orth-Mcneil Pharmaceutical, Inc. | Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists |
| DE10253282A1 (de) * | 2002-11-15 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung |
| PL1781298T4 (pl) * | 2004-04-22 | 2017-07-31 | Boehringer Ingelheim International Gmbh | Kombinacje leków zawierające benzoksazynę do leczenia chorób dróg oddechowych |
| DE102004024452A1 (de) * | 2004-05-14 | 2005-12-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Aerosolformulierung für die Inhalation von Betaagonisten |
-
2007
- 2007-08-15 UY UY30543A patent/UY30543A1/es not_active Application Discontinuation
- 2007-08-16 BR BRPI0715692-8A patent/BRPI0715692A2/pt not_active Application Discontinuation
- 2007-08-16 AU AU2007285746A patent/AU2007285746A1/en not_active Abandoned
- 2007-08-16 KR KR1020097005574A patent/KR20090040922A/ko not_active Withdrawn
- 2007-08-16 EP EP07819951A patent/EP2054034A2/de not_active Withdrawn
- 2007-08-16 US US11/839,817 patent/US20080041370A1/en not_active Abandoned
- 2007-08-16 WO PCT/EP2007/058515 patent/WO2008020056A2/de not_active Ceased
- 2007-08-16 EA EA200900267A patent/EA200900267A1/ru unknown
- 2007-08-16 JP JP2009525029A patent/JP2010501021A/ja active Pending
- 2007-08-16 CA CA002660480A patent/CA2660480A1/en not_active Abandoned
- 2007-08-16 PE PE2007001103A patent/PE20080607A1/es not_active Application Discontinuation
- 2007-08-16 MX MX2009001553A patent/MX2009001553A/es not_active Application Discontinuation
- 2007-08-17 TW TW096130612A patent/TW200817010A/zh unknown
- 2007-08-17 AR ARP070103672A patent/AR062424A1/es unknown
-
2009
- 2009-01-28 NO NO20090410A patent/NO20090410L/no not_active Application Discontinuation
- 2009-02-12 IL IL197024A patent/IL197024A0/en unknown
- 2009-03-18 CO CO09028166A patent/CO6150123A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008020056A2 (de) | 2008-02-21 |
| JP2010501021A (ja) | 2010-01-14 |
| CO6150123A2 (es) | 2010-04-20 |
| AU2007285746A1 (en) | 2008-02-21 |
| WO2008020056A3 (de) | 2008-09-12 |
| NO20090410L (no) | 2009-03-02 |
| IL197024A0 (en) | 2009-11-18 |
| TW200817010A (en) | 2008-04-16 |
| AR062424A1 (es) | 2008-11-05 |
| KR20090040922A (ko) | 2009-04-27 |
| UY30543A1 (es) | 2008-03-31 |
| MX2009001553A (es) | 2009-04-17 |
| EP2054034A2 (de) | 2009-05-06 |
| EA200900267A1 (ru) | 2009-08-28 |
| BRPI0715692A2 (pt) | 2013-08-06 |
| US20080041370A1 (en) | 2008-02-21 |
| CA2660480A1 (en) | 2008-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20080607A1 (es) | Formulacion en aerosol para la inhalacion de beta-agonistas | |
| PE20081319A1 (es) | Formulacion de aerosol para la inhalacion de agonistas beta | |
| PE20070708A1 (es) | Formulacion en aerosol para inhalacion de beta-agonistas | |
| EP2046287B1 (en) | Methods and compositions for the treatment and prevention of infections | |
| HRP20200998T1 (hr) | Postupak i sastav za liječenje okularne hipertenzije i glaukoma | |
| ES2826562T3 (es) | Solución para inhalación de tiotropio por nebulizador | |
| US20120093876A1 (en) | Ophthalmic Formulations, Methods Of Manufacture And Methods of Normalizing Meibomian Gland Secretions | |
| PE20040694A1 (es) | Derivados de benzoxazolinonas | |
| JP2013525493A5 (es) | ||
| JP2012520882A5 (es) | ||
| PE20060462A1 (es) | Combinacion farmaceutica que comprende derivados de benzoxazinona | |
| ES2353404T3 (es) | Nuevas combinaciones de medicamentos para el tratamiento de enfermedades de las vías respiratorias. | |
| PE20060239A1 (es) | Formulaciones en polvo para la inhalacion, las cuales contienen beta-agonista enantiomericamente puros | |
| AU2002221741B2 (en) | Inhalative solution formulation containing a tiotropium salt | |
| KR20100017166A (ko) | Ｎ-할로겐화 아미노산 제제 | |
| PE20060311A1 (es) | Formulacion en aerosol para la inhalacion de beta-agonistas | |
| CN105025896B (zh) | 澄清的水性液体制剂 | |
| ES2864735T3 (es) | Formulaciones oftálmicas que contienen gamma-lactamas sustituidas y métodos para el uso de las mismas | |
| CN105007918B (zh) | 稳定的水性液体制剂 | |
| JP2013525439A (ja) | ホスホニウム抗菌剤を含む薬学的組成物 | |
| AR038764A1 (es) | Formulacion de una solucion de inhalacion con una sal de tiotropio | |
| ES2432408T3 (es) | Formulaciones de aminoácidos N-halogenados que contienen ácidos alifáticos | |
| ES2784653T3 (es) | Composiciones de suspensión de finafloxacino | |
| CA2627726A1 (en) | Aerosolformulation for inhalation | |
| US20110319402A1 (en) | Aerosol formulation for the inhalation of beta agonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |